Clinical Trial: Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Postprandial Secretion of of Incretin Hormones and Incretin Effect in Patients With Maturity-onset Diabetes of the Young (MODY)

Brief Summary: The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and without treatment. In healthy subjects the purpose is also to investigate the incretin effect under increased levels of endogen incretin hormones.

Detailed Summary: Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.
Sponsor: University Hospital, Gentofte, Copenhagen

Current Primary Outcome: Incretin effect [ Time Frame: Within 1 year ]

The difference in insulin responses, as assessed by the area under curve (AUC) for plasma insulin and C-peptide concentrations, during the two different glucose stimuli: OGTT and isoglycemic iv glucose infusion aswell as after a test meal in MODY-patients compared to healthy control subjects.


Original Primary Outcome: Incretin effect [ Time Frame: Within 1 year ]

The difference in insulin responses, as assessed by the area under curve (AUC) for plasma insulin and C-peptide concentrations, during the two different glucose stimuli: OGTT and isoglycemic iv glucose infusion in MODY-patients compared to healthy control subjects.


Current Secondary Outcome:

  • Plasma GLP1 response [ Time Frame: Within 1 year ]
    Comparing GLP1 responses of the different experimental days, compared to healthy control subjects.
  • Plasma GIP response [ Time Frame: Within 1 year ]
    Comparing GIP responses of the different experimental days, compared to healthy control subjects.
  • Plasma glucagon response [ Time Frame: Within 1 year ]
    Comparing glucagon responses of the different experimental days, compared to healthy control subjects.


Original Secondary Outcome: Same as current

Information By: University Hospital, Gentofte, Copenhagen

Dates:
Date Received: April 13, 2011
Date Started: January 2011
Date Completion:
Last Updated: January 14, 2013
Last Verified: January 2013